Popular search terms:
Search Results
102 results found-
Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.
https://www.cslseqirus.us/news -
CSL Seqirus is a world leader in developing and producing influenza vaccines. Learn more about how we work with our partners to protect the global community.
https://www.cslseqirus.us/products -
Influenza is a common, highly contagious infection that can lead to life-threatening complications. Learn more about influenza and our cutting-edge vaccines.
https://www.cslseqirus.us/expertise/influenza -
CSL Seqirus brings multifaceted expertise to influenza prevention, employing both egg and cell-based technologies to meet the global community's needs.
https://www.cslseqirus.us/expertise -
CSL Seqirus is the only manufacturer to offer a differentiated influenza vaccine for all eligible people aged six months and older in the United States.
https://www.cslseqirus.us/news/csl-seqirus-begins-shipping-its-portfolio-of-influenza-vaccines-for-the-2024-25-flu-season -
Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.
https://www.cslseqirus.us/news/csl-seqirus-presents-data-at-idweek-2024 -
Results from real-world evidence (RWE) studies to be presented at OPTIONS XII show the effectiveness of cell-based and MF59® adjuvanted influenza vaccines.
https://www.cslseqirus.us/news/csl-seqirus-presents-real-world-evidence-at-options-xii-conference -
Learn more about how we're leveraging cutting-edge technology and proven expertise to develop influenza vaccines and respond to pandemic threats.
https://www.cslseqirus.us/ -
Results of the first season of a randomized study showed adjuvanted and high-dose influenza vaccines did not differ in effectiveness against PCR-confirmed influenza.
https://www.cslseqirus.us/news/new-data-presented-at-idweek-2024 -
CSL Seqirus has been on the front line of pandemic preparedness for more than a century. Learn more about our rapid vaccine production capabilities.
https://www.cslseqirus.us/expertise/influenza/pandemic-response-solutions